Literature DB >> 788772

Blast crisis of chronic myeloid leukaemia (CML). II. Cell surface marker analysis of "lymphoid" and myeloid cases.

G Janossy, M F Greaves, T Revesz, T A Lister, M Roberts, J Durrant, B Kirk, D Catovsky, M E Beard.   

Abstract

Fourteen cases of philadelphia chromosome (Ph1) positive chronic myeloid leukaemia in blast transformation have been investigated using cell surface markers. Morphologically eight cases were lymphoid and the remainder myeloid in appearance. All cases were negative with surface markers for thymocytes and T and B lymphocytes. Five of the lymphoid cases reacted with an antiserum specific for acute lymphoid leukaemia )ALL) of non-T non-B type and were also weakly reactive with a lymphocyte reactive antiserum. A sixth patient, whose blast cells were anti-ALL negative (ALL-) at presentation, subsequently developed central nervous system leukaemia with anti-ALL positive (ALL+) blast cells in the CSF. In all cases the leukaemic blast cells showed greatly diminished expression of cholera toxin receptors when compared to granulocytic cells from the chronic phase of CML. This parallels weak or negligible expression of the cholera toxin receptor in ALL and AML. These results suggest that the blastic phase of CML may involve different cellular derivatives of a pluripotential stem cell in which the primary malignant/genetic changes reside. The blast crisis of CML can therefore be heterogeneous with respect to cellular expression and in a significant proportion of patients involves a cell which is by membrane markers and morphological criteria indistinguishable from that seen in the common form of ALL. In these cases the Philadelphia chromosome may be the only distinguishing cellular characteristic.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788772     DOI: 10.1111/j.1365-2141.1976.tb00189.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Monoclonal gammopathy in chronic myeloproliferative disorders.

Authors:  T Economopoulos; J Economidou; E Papageorgiou; J Dervenoulas; C Christodoulides; V Pappa; D Karakassis; C Terzoglou; S Athanassiadou; G Chalevelakis
Journal:  Blut       Date:  1989-01

2.  Difficulties in leukaemia diagnosis.

Authors: 
Journal:  Br Med J       Date:  1977-03-26

3.  Megakaryoblastic transformation of chronic granulocytic leukaemia. An electron microscopy and cytochemial study.

Authors:  B Bain; D Catovsky; M O'Brien; A S Spiers; G H Richards
Journal:  J Clin Pathol       Date:  1977-03       Impact factor: 3.411

4.  Long remission after lymphoblastic transformation of chronic granulocytic leukaemia.

Authors:  M V Joyner; P Dujardin; J P Cassuto; P Audoly; M Schneider
Journal:  Br Med J       Date:  1978-06-10

5.  Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia.

Authors:  A N Stark; C S Scott; B Bhatt; B E Roberts
Journal:  J Clin Pathol       Date:  1986-07       Impact factor: 3.411

6.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

7.  Familial leukemia: Ph1 positive acute lymphoid leukemia of a mother and her infant.

Authors:  E Oláh; V Stenszky; A Kiss; I Kovács; E Balogh; L Karmazsin
Journal:  Blut       Date:  1981-10

8.  Marker profiles of human leukemia and lymphoma cell lines.

Authors:  J Minowada; H Koshiba; K Sagawa; I Kubonishi; M S Lok; E Tatsumi; T Han; B I Srivastava; T Ohnuma
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

9.  Demonstration of feline and canine platelet glycoproteins by immuno- and lectin histochemistry.

Authors:  J Darbès; F Colbatzky; G Minkus; W Hermanns
Journal:  Histochemistry       Date:  1993-07

10.  Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.

Authors:  B Anger; F Carbonell; I Braunger; B Heinze; W Gutensohn; E Thiel; H Heimpel
Journal:  Blut       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.